Anumana and Novartis partner for AI-based heart disease detection

Related Articles
New Project Trains AI on a Hard-to-Diagnose Cardiac Issue
Health Leaders: A start-up from the Mayo Clinic orbit is partnering with Pfizer to develop an AI-enhanced ECG that can detect cardiac amyloidosis, a progressive disease that's difficult to diagnose…December 16, 2022
Anumana Welcomes Dr. Simos Kedikoglou as New COO
Investor Hangout: Anumana, a prominent player in AI-driven health technology, has recently appointed Dr. Simos Kedikoglou as its new President and Chief Operating Officer (COO). This exciting change will see…January 10, 2025
Tackling Imbalanced Regression in Clinical AI with KDE-weighted Deep Models
Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…December 05, 2025
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
AI Thority: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…July 12, 2022


